Surgery Partners Reports $77.9M Attributable Net Loss in 2025 10-K Despite Revenue Growth
SGRY is trading near its 52-week low of $13.135 (7.1% below the low) on elevated volume (2.0× avg).
Summary
Surgery Partners filed its 2025 10-K, reporting total revenues of $3.31 billion, a 6.2% increase year-over-year, driven by same-facility growth and acquisitions. Despite this top-line growth and an increase in adjusted EBITDA to $526 million, the company reported a net loss attributable to Surgery Partners of $(77.9) million for the fiscal year. This attributable net loss, despite a reported net income of $98.9 million, will significantly impact earnings per share and is a key concern for investors, especially with the stock trading near its 52-week low. Traders will be evaluating the drivers of this attributable loss and its implications for future profitability and valuation.
At the time of this announcement, SGRY was trading at $12.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $13.14 to $25.05. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.